Navigation Links
IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors

NEW YORK, Oct. 29, 2012 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("Company") (SVFC) announced today that Myron Z. Holubiak has joined the IntelliCell Board of Directors.  Mr. Holubiak is an accomplished biotech and pharmaceutical senior executive with over 30 years of industry experience including directing Roche Laboratories, a $2.8 billion dollar company with over 3,500 employees, as its President.  Mr. Holubiak also serves as Director for Ventrus BioSciences, Inc. and Chairman of the Board for BioScrip, Inc. 

IntelliCell's Chairman and CEO, Dr. Steven Victor, stated, "Our Company is very pleased to announce today that Myron Holubiak is joining our Board of Directors.  He is bringing a wealth of industry experience and accomplishments to our executive team.  I look forward to working with him to assist IntelliCell in its growth strategies as the Company continues its thought leadership role as a preeminent Regenerative Medicine organization."

Said Mr. Holubiak, "The decades of scientific research into regenerative medicine is now showing dramatic results and fulfilling the promise we all had hoped for.

"Dr. Victor's pioneering efforts in the advancement of the science and his innovations in the use of ultrasonic cavitation is now setting the standard for the harvest of autologous stromal vascular fractions that are demonstrating promise in clinical efficacy.

"I am pleased to join the board of IntelliCell. The company is committed to far reaching clinical research in the treatment of osteoarthritis, diabetic ulcers, bone and dermal conditions where regenerative processes are desperately needed.

"I look forward to participating in the growth of IntelliCell at such an exciting time."

About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

IntelliCell BioSciences, Inc.
Robert J. Sexauer
Email Contact:  
(646) 576-8706  

SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
2. IntelliCell BioSciences Expands Management Team
3. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
4. AMRI Announces Strategic Contract with Knopp Biosciences
5. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
6. Neurocrine Biosciences Reports Second Quarter 2012 Results
7. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
8. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
9. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
10. Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
11. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between the ... has been formalized with the signing of a Memorandum of Understanding. , AMA ... Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
Breaking Biology Technology:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
Breaking Biology News(10 mins):